Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03397199
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03389087
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03383237
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03376737
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Study of BCMA CAR-T in Multiple Myeloma
Phase 1
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03322735
- Locations
- 🇨🇳
Cancer Hospital Affiliate to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Phase 1
- Conditions
- B-cell Acute Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03263208
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Apatinib Treatment for Advanced Esophagus Cancer
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03170310
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03163381
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer
Not Applicable
Withdrawn
- Conditions
- Hyperthermic PerfusionLung CancerEsophageal Cancer
- Interventions
- Other: hyperthermic perfusion
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Henan Cancer Hospital
- Registration Number
- NCT03110939
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Phase 1
- Conditions
- B Cell Lymphoma
- Interventions
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03101709
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath